AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11791949 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (Bupropion SR and Methylphenidate)
Number of subjects: 30
Study 10408666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (400 mg/day) for 60 days
Number of subjects: 384
Study 10408666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus arginine supplementation (4 g/day) for 60 days
Number of subjects: 384
Study 10408666 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccine only)
Number of subjects: 384
Study 8055863 — intervention group
Group type: COMPARATOR
Intervention: Advice Only (AO)
Number of subjects: 1261
Study 8055863 — intervention group
Group type: COMPARATOR
Intervention: Counseling Intervention (CI)
Number of subjects: 1261
Study 8055863 — intervention group
Group type: COMPARATOR
Intervention: Counseling plus Nicotine-Containing Gum (CI + NCG)
Number of subjects: 1261
Study 2568065 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium alone
Number of subjects: 60
Study 2568065 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium plus 600 IU of vitamin E
Number of subjects: 60
Study 2568065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31439007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-equipped insoles combined with photo documentation and smartphone application (Smart Prevent Diabetic Feet Application) for daily foot temperature measurements.
Number of subjects: 300
Study 31439007 — intervention group
Group type: COMPARATOR
Intervention: Education about regular foot care provided to both groups.
Number of subjects: 300
Study 27937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) - 9 capsules (350 mg/capsule) per day for 3 months
Number of subjects: 40
Study 27937077 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 9 capsules per day for 3 months
Number of subjects: 40
Study 25275693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal insert containing 10 mg timed-release dinoprostone (PGE2)
Number of subjects: 52
Study 25275693 — intervention group
Group type: COMPARATOR
Intervention: Double-balloon catheter
Number of subjects: 52
Study 22641110 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary stenting (PTBS)
Number of subjects: 142
Study 22641110 — intervention group
Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 142
Study 21632072 — intervention group
Group type: COMPARATOR
Intervention: Exercise regimen (submaximal at 35% ± 5% or maximal oxygen consumption)
Number of subjects: 17
Study 19497091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 1200 mg orally twice daily for two doses before and two doses after the procedure
Number of subjects: 2300
Study 19497091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2300
Study 16123767 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine
Number of subjects: 12
Study 16123767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15151264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol pulse doses (2‐8 mcg/3x/week)
Number of subjects: 18
Study 15151264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 11488772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (ADM) infusion (1-30 pmol x min(‐1))
Number of subjects: 8
Study 11488772 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin N‐terminal 20 peptide (PAMP) infusion (100-3000 pmol x min(‐1))
Number of subjects: 8
Study 11488772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (ADM) co-infused with NEP inhibitor thiorphan (30 nmol x min(‐1))
Number of subjects: 8
Study 11488772 — intervention group
Group type: COMPARATOR
Intervention: Adrenomedullin (ADM) co-infused with control vasoconstrictor noradrenaline (120 pmol x min(‐1))
Number of subjects: 8
Study 9138439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin
Number of subjects: 49
Study 9138439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8154874 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 25
Study 8154874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3046645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg three times a day) plus dipyridamole (75 mg three times a day) for a mean of 25 months, with warfarin for three months.
Number of subjects: 320
Study 3046645 — intervention group
Group type: COMPARATOR
Intervention: Placebo for a mean of 23 months, with warfarin for three months.
Number of subjects: 320
Study 29805116 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg/day for 2 weeks
Number of subjects: 133
Study 29805116 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat (varied doses: 5 mg/day, 10 mg/day, or 15 mg/day) for 52 weeks
Number of subjects: 133
Study 29805116 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 133
Study 28277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin® 200 mg/day (Group A)
Number of subjects: 146
Study 28277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin® 300 mg/day (Group B)
Number of subjects: 146
Study 28277886 — intervention group
Group type: COMPARATOR
Intervention: Endometrin® 200 mg/day (control group)
Number of subjects: 146
Study 26194656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25 % (40 ml)
Number of subjects: 60
Study 26194656 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25 % (40 ml)
Number of subjects: 60
Study 26194656 — intervention group
Group type: COMPARATOR
Intervention: Desflurane alone (Control group)
Number of subjects: 60
Study 24281309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 30
Study 24281309 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 30
Study 21923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 10
Study 21923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 μg
Number of subjects: 10
Study 18662624 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery without cardiopulmonary bypass
Number of subjects: 66
Study 18662624 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery with cardiopulmonary bypass
Number of subjects: 66
Study 16585121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 60
Study 16585121 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg
Number of subjects: 60
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with DLHigh
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with DLLow
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Each active drug with DLHigh
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Each active drug with DLLow
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: No drugs with IQ > median
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: One drug with IQ > median
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drugs with IQ > median
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drugs with IQ > median
Number of subjects: 137
Study 12004271 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or five drugs with IQ > median
Number of subjects: 137
Study 10213434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 38
Study 10213434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 38
Study 7605186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous orphenadrine citrate (60mg)
Number of subjects: 11
Study 7605186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2189123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (0, 15, 30, or 60 mg daily for six months)
Number of subjects: 26
Study 478162 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg t.d.s before meals)
Number of subjects: 14
Study 478162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 478162 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14
Study 6818587 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41
Study 6818587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6818587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 41
Study 6818587 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 41
Study 31486723 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of an advance directive (AD) with targeted ACP messaging
Number of subjects: 45
Study 31486723 — intervention group
Group type: EXPERIMENTAL
Intervention: AD, messaging, plus prompting patients to engage with the Prepare For Your Care website (PREPARE)
Number of subjects: 45
Study 31486723 — intervention group
Group type: EXPERIMENTAL
Intervention: AD, messaging, PREPARE, plus Care Coordinator engagement with patients and clinicians
Number of subjects: 45
Study 31486723 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study 29498351 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ca fat-free milk phase (MD) - approximately 1500 mg of Ca/d
Number of subjects: 14
Study 29498351 — intervention group
Group type: COMPARATOR
Intervention: Low-Ca phase (CD) - approximately 800 mg of Ca/d
Number of subjects: 14
Study 26224203 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A inducers (phenobarbital, phenytoin, carbamazepine)
Number of subjects: 153
Study 26224203 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 inducers (valproic acid, phenobarbital, phenytoin, carbamazepine)
Number of subjects: 153
Study 26224203 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 inhibitors (felbamate, oxcarbazepine)
Number of subjects: 153
Study 26224203 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of AEDs that are either CYP450 inhibitors or inducers with clobazam
Number of subjects: 153
Study 24625755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimney stove
Number of subjects: 45
Study 24625755 — intervention group
Group type: COMPARATOR
Intervention: Open fire
Number of subjects: 45
Study 22484031 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 29
Study 22484031 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 20044310 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 20
Study 20044310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17109385 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.08 mL/kg/min
Number of subjects: 36
Study 17109385 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.11 mL/kg/min
Number of subjects: 36
Study 17109385 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.14 mL/kg/min
Number of subjects: 36
Study 17109385 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) at all infusion rates
Number of subjects: 36
Study 17109385 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) at 0.14 mL/kg/min
Number of subjects: 36
Study 16239186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prostheses (Group A)
Number of subjects: 782
Study 16239186 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented tissue prostheses (Group B)
Number of subjects: 782
Study 16239186 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless tissue valves (Group C)
Number of subjects: 782
Study 16239186 — intervention group
Group type: COMPARATOR
Intervention: Preoperative factors (poor ejection fraction < 35%, left atrial enlargement, left bundle branch block)
Number of subjects: 782
Study 16239186 — intervention group
Group type: COMPARATOR
Intervention: Perioperative variables (bypass time > 100 minutes with x-clamp time > 70 minutes)
Number of subjects: 782
Study 11862176 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing Recovery System (RRS, Neutrogena)
Number of subjects: 42
Study 11862176 — intervention group
Group type: COMPARATOR
Intervention: Silon-TSR (Bio Med Sciences) followed by Aquaphor ointment
Number of subjects: 42
Study 10208595 — intervention group
Group type: EXPERIMENTAL
Intervention: real‐rTMS applied to M1 contralaterally to the more severely affected limb
Number of subjects: 12
Study 10208595 — intervention group
Group type: COMPARATOR
Intervention: sham‐rTMS applied 3 cm anteriorly to Fz
Number of subjects: 12
Study 8548053 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 micrograms/day for 4 months preoperatively)
Number of subjects: 60
Study 8548053 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 60
Study 8548053 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide followed by Surgery
Number of subjects: 60
Study 8548053 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 60
Study 2237768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential gradient intermittent pneumatic compression applied for 4 hours each day.
Number of subjects: 45
Study 2237768 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with ulcer debridement, cleaning, nonadherent dressing, and graduated compression stockings).
Number of subjects: 45
Study 672548 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively increased pedalling rate (P)
Number of subjects: 29
Study 672548 — intervention group
Group type: COMPARATOR
Intervention: Resistance (R)
Number of subjects: 29
Study 31953732 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic pancreatoduodenectomy (RPD) using a standardized 17 steps approach
Number of subjects: 0
Study 31953732 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized surgical approach
Number of subjects: 0
Study 31953732 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic pancreatoduodenectomy (RPD)
Number of subjects: 0
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessments (Total Neuropathy Score, reduced)
Number of subjects: 316
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessments (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire)
Number of subjects: 316
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool grading (NCI-CTCAE)
Number of subjects: 316
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO screening tools
Number of subjects: 316
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a brief objective test
Number of subjects: 316
Study 31374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tools
Number of subjects: 316
Study 28957556 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 508
Study 28957556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab or prednisone and SSZ)
Number of subjects: 508
Study 28957556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 508
Study 25692241 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 825
Study 25692241 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (3 mg)
Number of subjects: 825
Study 23645763 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell-enriched lymphocytes (NKL) with docetaxel
Number of subjects: 19
Study 23645763 — intervention group
Group type: COMPARATOR
Intervention: Historical control of weekly docetaxel regimen
Number of subjects: 19
Study 20680427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 24% oxygen at 1.3 ATA for 40 sessions
Number of subjects: 16
Study 19444001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 22
Study 19444001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 22
Study 19444001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Amitriptyline 75 mg/day and Fluvoxamine 100 mg/day)
Number of subjects: 22
Study 17185129 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha/AH Plus
Number of subjects: 0
Study 17185129 — intervention group
Group type: COMPARATOR
Intervention: Resilon/Epiphany
Number of subjects: 0
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion SPECT
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction lower than 60%
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal peak filling rate
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal time to peak filling rate
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed defects
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction lower than 60%
Number of subjects: 101
Study 15472643 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality and complications
Number of subjects: 101
Study 12131253 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity of at least moderate intensity (30 min x d(‐1) or more)
Number of subjects: 424
Study 12131253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling
Number of subjects: 424
Study 12131253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 424
Study 12131253 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased physical activity over the past 5 years
Number of subjects: 424
Study 9475648 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (5 mL x kg(‐1) every 30 min)
Number of subjects: 13
Study 9475648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 13
Study 9475648 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 13
Study 8582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (10% triglyceride emulsion) at a rate of 0.4 ml/min with heparin (200 U bolus followed by 0.2 U/min per kg body weight) for 24 hours
Number of subjects: 12
Study 8582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (10% triglyceride emulsion) for 24 hours
Number of subjects: 12
Study 8582538 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% NaCl infusion)
Number of subjects: 12
Study 8582538 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery test after discontinuation of Intralipid infusion
Number of subjects: 12
Study 2215098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (2 mL 4% lidocaine solution injected through the catheter)
Number of subjects: 20
Study 2215098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special management)
Number of subjects: 20
Study 380941 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS), 30 mg/kg
Number of subjects: 90
Study 380941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (DSP), 6 mg/kg
Number of subjects: 90
Study 380941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 90
Study 31003229 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (300 U, mandatory ankle plantar flexors; ≤100 U, optional lower-limb muscles)
Number of subjects: 468
Study 31003229 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (mandatory muscles alone)
Number of subjects: 468
Study 31003229 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (additional injections into toe muscles: flexor digitorum longus, flexor hallucis longus)
Number of subjects: 468
Study 31003229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 30207586 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-negative participants
Number of subjects: 269
Study 30207586 — intervention group
Group type: COMPARATOR
Intervention: Amyloid-positive participants
Number of subjects: 269
Study 26903253 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Group Therapy for SMD, 11-week duration, participants stabilized on psychostimulant medication.
Number of subjects: 68
Study 26903253 — intervention group
Group type: COMPARATOR
Intervention: Community-based psychosocial treatment, control group.
Number of subjects: 68
Study 24184523 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-assisted coiling
Number of subjects: 361
Study 24184523 — intervention group
Group type: COMPARATOR
Intervention: Coiling alone
Number of subjects: 361
Study 21658722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (Group B)
Number of subjects: 80
Study 21658722 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritrocal and intraperitoneal ropivacaine (Group D)
Number of subjects: 80
Study 21658722 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritrocal ropivacaine (Group C)
Number of subjects: 80
Study 21658722 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 80
Study 19153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein diet (HP)
Number of subjects: 48
Study 19153580 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate diet (HC)
Number of subjects: 48
Study 19153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-supplemented HP diet
Number of subjects: 48
Study 19153580 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-supplemented HP diet
Number of subjects: 48